|Actinium Pharmaceuticals Inc., of New York||Actimab-A||Antibody radiation conjugate that targets CD33 receptor on blood cancer cells and delivers cytotoxic radiation via radioisotope Actinium-225||Relapsed or refractory acute myeloid leukemia||First patient treated in third cohort|
|Arch Biopartners Inc., of Toronto||Metablok||LSALT peptide||Organ damage caused by inflammation||Cohort of eight healthy volunteers added|
|Auris Medical Holding Ltd., of Hamilton, Bermuda||AM-201||Intranasal betahistine||Prevention of antipsychotic-induced weight gain and somnolence||Last patient had last treatment visit|
|Debiopharm International SA, of Lausanne, Switzerland||Debio-0123||WEE-1 inhibitor||Advanced solid tumors||Trial begun|
|Dynacure SAS, of Strasbourg, France||DYN-101||Antisense medicine designed to modulate expression of dynamin 2||Myotubular and centronuclear myopathies||First patient dosed|
|Psioxus Therapeutics Ltd., of Oxford, U.K.||NG-641||4-transgene tumor-microenvironment-modifying cancer gene therapy||Solid tumors||Started Star study to assess safety, tolerability and preliminary antitumor activity|
|Auris Medical Holding Ltd., of Hamilton, Bermuda||AM-125||Intranasal betahistine||Acute peripheral vertigo||In addition to the ongoing intranasal dose-escalation portion, open-label testing of oral betahistine for reference purposes has commenced|
For more information about individual companies and/or products, see Cortellis.